Skip to main content Skip to navigation
RB705 Hamster Anti-Mouse TCR Vβ3
Product Details
Down Arrow Up Arrow


BD OptiBuild™
TCR V beta 3; TCR Vβ3
Mouse (Tested in Development)
Armenian Hamster IgG2, κ
αβ TCR purified from mouse T-cell hybridoma 2B4.6
Flow cytometry (Qualified)
0.2 mg/ml
100039790
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  3. For U.S. patents that may apply, see bd.com/patents.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
  8. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
  9. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  10. An isotype control should be used at the same concentration as the antibody of interest.
  11. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
  12. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
757958 Rev. 1
Antibody Details
Down Arrow Up Arrow
KJ25

The KJ25 antibody specifically reacts with the Vβ 3 T-cell Receptor (TCR) of strains having the a (e.g., C57BR, SJL), b (e.g., AKR, CBA/Ca, C57BL, DBA/1), and c (e.g., RIII) haplotypes of the Tcrb gene complex. Vβ 3 TCR-bearing T lymphocytes are clonally eliminated either completely or partially in mice expressing superantigens encoded by the Mtv-1 (Mls-4[a], Mls[c]), Mtv-3 (Mls[c]), Mtv-6 (Mls-3[a], Mls[c]), Mtv-13 (Mls-2[a], Mls[c]), Mtv-27, Mtv-44, and/or Mtv-MAI endogenous proviruses (e.g., A, BALB/c, CBA/J, C3H/He, DBA/2, NZB, NZW). Vβ 3 TCR-bearing T cells are activated by the superantigenic Staphylococcal Enterotoxins A and B. Activation or elimination of Vβ 3 TCR-expressing T cells by these determinants is partially dependent upon presentation by I-E. This hamster mAb to a mouse leukocyte antigen does not cross-react with rat leukocytes.

757958 Rev. 1
Format Details
Down Arrow Up Arrow
RB705
The BD Horizon RealBlue™ 705 (RB705) Dye is part of the BD® family of blue dyes. It is a tandem fluorochrome with an excitation maximum (Ex Max) at 498-nm and an emission maximum (Em Max) at 707-nm as measured using an antibody-dye conjugate. Driven by BD® innovation, RB705 can be used on both spectral and conventional cytometers and is designed to be excited by the Blue laser (488-nm) with minimal excitation by the 561-nm Yellow-Green laser. For conventional instruments equipped with a Blue laser (488-nm), RB705 can be used as an alternative to PerCP-Cy5.5 or BB700 and we recommend using an optical filter centered near 710-nm (e.g., a 695/40 or 710/50-nm bandpass filter). For spectral instruments equipped with a Blue laser (488-nm), it can be used in conjunction with PerCP-Cy5.5. RB705 is on average brighter than PerCP-Cy5.5 and BB700, and has minimal spillover into Yellow-Green detectors.
altImg
RB705
Blue 488 nm
498 nm
707 nm
757958 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (8)

  1. Fairchild S, Rosenwasser OA, Dyson PJ, Tomonari K. Tcrb-V3+ T-cell deletion and a new mouse mammary tumor provirus, Mtv-44. Immunogenetics. 1992; 36(3):189-194. (Biology). View Reference
  2. Hodes RJ, Abe R. Mouse endogenous superantigens: Ms and Mls-like determinants encoded by mouse retroviruses.. Curr Protoc Immunol. 2001; Appendix 1:Appendix 1F. (Biology). View Reference
  3. McCormack JE, Callahan JE, Kappler J, Marrack PC. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol. 1993; 150(9):3785-3792. (Biology). View Reference
  4. Pullen AM, Marrack P, Kappler JW. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature. 1988; 335(6193):796-801. (Immunogen). View Reference
  5. Tomonari K, Fairchild S, Rosenwasser OA. Influence of viral superantigens on V beta- and V alpha-specific positive and negative selection. Immunol Rev. 1993; 131:131-168. (Biology). View Reference
  6. Tomonari K, Fairchild S, Rosenwasser OA. Tcrb-V3+ T-cell deletion and a mouse mammary tumor provirus, Mtv-27. Immunogenetics. 1992; 36(5):302-305. (Biology). View Reference
  7. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell. 1989; 56(1):27-35. (Biology). View Reference
  8. Yuuki H, Yoshikai Y, Kishihara K, et al. Deletion of self-reactive T cells in nude mice grafted with neonatal allogeneic thymus. J Immunol. 1990; 144(2):474-479. (Biology). View Reference
View All (8) View Less
757958 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.